SAM produced by methionine metabolism promotes the malignant biological behavior of tumor cells and inhibits the differentiation and functional roles of immune cells, so targeting MAT2A is expected to be a promising target to promote gastric cancer therapy. Here, MAT2A is linked to neoplasm.